Last reviewed: July 9, 2026
Last updated: July 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active compound in Wegovy, works by slowing stomach emptying and signaling fullness to the brain. Clinical trials show patients lose an average of 15% of their starting weight over 68 weeks, but individual timelines vary significantly based on starting weight, dose escalation, and metabolic response.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
Weight Loss Results in the First Four Weeks
During the first month of semaglutide therapy, most patients experience modest weight loss of 2–5 pounds. This early phase focuses on dose tolerance and appetite adjustment rather than dramatic fat loss. Many users report reduced cravings and smaller meal portions, which naturally lead to lower calorie intake without restrictive dieting.
Initial water weight loss accounts for some early results, but the appetite-suppressing effect of semaglutide typically becomes noticeable within 7–10 days. Patients beginning compounded semaglutide from licensed 503A pharmacies follow the same titration schedule as branded Wegovy, starting at 0.25 mg weekly. PlexusDx maintains transparent pricing at $189/month regardless of dose level—your medication cost stays flat even as your therapeutic dose increases.
Month Two and Three: Accelerating Weight Loss
Weeks 5–12 typically bring 5–15 pounds of additional weight loss as patients reach therapeutic doses and their bodies adapt to reduced calorie consumption. The appetite-suppressing effect strengthens during this window, and many users report sustained satisfaction with smaller portions. Metabolic adaptation begins during this phase, meaning the body's energy expenditure adjusts to match lower food intake.
By the end of week 12, cumulative weight loss often reaches 10–20 pounds for individuals starting at higher body weights. This acceleration occurs because semaglutide increases GLP-1 receptor signaling in the hypothalamus, the brain region controlling hunger and satiety. Compounded semaglutide delivered via weekly injection produces identical biological effects to branded formulations, with PlexusDx patients following the same evidence-based dosing progression.
Months Four Through Twelve: Sustained Progress
After 16 weeks of consistent semaglutide therapy, weight loss typically continues at a steady pace of 1–2 pounds per week. Patients who maintain lifestyle changes—including higher protein intake and regular movement—achieve cumulative losses of 20–35 pounds by month six. The appetite suppression remains stable at maintenance doses, ranging from 1.7 mg to 2.4 mg weekly.
Long-term clinical data shows that patients continuing semaglutide for a full year lose an average of 35–50 pounds, or roughly 15% of their starting body weight. However, results plateau without adherence to nutritional guidelines and physical activity. PlexusDx compounded semaglutide injections cost $189/month at the starter tier, making year-long treatment significantly more affordable than branded alternatives for patients without insurance coverage.
Factors That Influence Individual Weight Loss Speed
Starting body weight, age, metabolic rate, and adherence to the medication schedule all shape how quickly someone loses weight on semaglutide. Patients with higher initial body mass index typically see faster absolute weight loss in the first 12 weeks. Genetic predispositions affecting GLP-1 receptor sensitivity and metabolic pathways also influence individual response—factors that PlexusDx addresses through the Precision Peptide Genetic Test.
The test analyzes 14 metabolic pathways and 49 peptides, including key variants in FTO gene (rs9939609), which directly correlate with semaglutide response potential. Patients with favorable genetic profiles for GLP-1 pathway sensitivity often achieve faster weight loss trajectories. PlexusDx adds the Precision Peptide Genetic Test as $298, enabling personalized insight into your metabolic response before dose adjustments.
Realistic Expectations: Comparing Wegovy Timelines to Real-World Data
Pharmaceutical trials conducted under strict dietary and exercise protocols report higher weight loss percentages than real-world patients typically achieve. A meta-analysis of semaglutide trials showed 15% average body weight reduction, but many patients in everyday practice achieve 8–12% reduction. This difference reflects normal variation in dietary adherence, physical activity levels, and metabolic individuality outside controlled research environments.
Compounded semaglutide from licensed 503A pharmacies delivers the same active pharmaceutical ingredient as Wegovy, meaning weight loss timelines and percentages remain identical to branded formulations. PlexusDx serves all 50 states without insurance requirements, HSA and FSA eligibility accepted, and pricing remains flat at $189/month—ensuring affordability does not compromise the speed or magnitude of clinical results. Early plateau or slower-than-expected loss may warrant genetic testing through PlexusDx to identify whether alternative GLP-1 compounds like tirzepatide offer better individual response potential.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.
Frequently Asked Questions
How much weight should I expect to lose in my first month on semaglutide?
Most patients lose 2–5 pounds in the first four weeks as their body adjusts to appetite suppression and reduced calorie intake. This early phase establishes tolerance and begins the medication's fullness-signaling effect. PlexusDx compounded semaglutide follows the same titration and weight loss timeline as brand-name Wegovy.
Is the weight loss speed the same for everyone taking semaglutide?
No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Does compounded semaglutide from PlexusDx produce the same weight loss results as brand-name Wegovy?
Yes—PlexusDx sources compounded semaglutide from licensed 503A pharmacies using identical pharmaceutical-grade compounds as Wegovy. Weight loss timelines, percentages, and mechanisms are identical to branded formulations. PlexusDx pricing is $189/mo month-to-monthnth flat, with no insurance required and HSA/FSA eligibility, making results accessible at lower cost.
What should I do if my weight loss slows or plateaus after three months?
Weight loss plateau is common after 4–6 months as the body reaches a new metabolic equilibrium. Reassessing dietary protein intake, increasing movement, or extending the semaglutide dose may restart progress. PlexusDx offers alternative compounds—including compounded tirzepatide ($289/month) or dual-compound GLP-Squared ($289/month)—for patients whose response to semaglutide alone plateaus.
How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?
No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Do You Start to Notice Weight Loss on Ozempic?
What Does Ozempic Do to Your Appetite?